Course Number and Title: PCL368H1S: DRUG DEVELOPMENT PIPELINE I: IN VITRO (8T, 40P)
Course Description: This course will provide a learning experience that parallels and simulates the process, protocols, methods and evaluation tools used for later-stage in vivo drug development. Modules will build on the student's fundamental knowledge and simulate the thought processes and techniques used during drug development in research institutes, clinical research organizations and pharmaceutical and biotechnology companies worldwide. Modules will include pharmacokinetic and pharmacodynamic analyses and pharmacogenetic screening approaches in model systems and humans. This experience will allow students to leverage their learned skills and knowledge to improve their comprehension and employability in this area, while honing critical thinking and analytical skills.
Estimated Course Enrolment: 60
Estimated TA support: 4 TAs
Schedule: Thursday 1:30-5:30
Sessional dates: January 9, 2023 - April 29, 2023
Salary: SL1: $1,018.76, SL1 LT: $1,064.13, SL2: $1,090.27, SL3: $1,116.23 (rates reflect remuneration for teaching 0.06 FCE)
Qualifications
A minimum BScH in Pharmacology or other related field is preferred and will be enrolled as a trainee at the University of Toronto. The individual will have excellent knowledge of general pharmacology, extensive experience in teaching lab development, demonstration, and teaching. Applied and documented knowledge of R and other data analysis skills recommended. The candidate will be familiar with various techniques used in drug development in both pre-clinical research and experience with GCP, GLP and GMP. The candidate should have extensive experience in course management (Quercus preferred), creating and delivering online and in person student assessments and examinations, course delivery, working with graduate students and faculty and mentoring undergraduate students.
Description of duties:
MNCJobz.com will not be responsible for any payment made to a third-party. All Terms of Use are applicable.